《公司業績》人保集團(01339.HK)半年純利168.55億人民幣升33.7% 中期息1.71分人民幣
中國人民保險集團(01339.HK)公布截至今年6月底止中期業績,總保費收入3,441.31億元人民幣(下同),按年升2.2%。純利168.55億元,按年升33.7%;每股盈利0.38元。中期股息1.7分。
6月30日,綜合償付能力充足率318%,較2020年末提高13個百分點;核心償付能力充足率269%,較2020年年末上升12個百分點。
人保壽險半年新業務價值跌25.2%至24.12億元,人保健康半年新業務價值增116.1%至7.11億元。
集團總投資收益按年增34.9%至353.62億元;總投資收益率上升1.2個百分點至6.7%。
Follow us
Find us on
Facebook,
Twitter ,
Instagram, and
YouTube or frequent updates on all things investing.Have a financial topic you would like to discuss? Head over to the
uSMART Community to share your thoughts and insights about the market! Click the picture below to download and explore uSMART app!

Disclaimers
uSmart Securities Limited (“uSmart”) is based on its internal research and public third party information in preparation of this article. Although uSmart uses its best endeavours to ensure the content of this article is accurate, uSmart does not guarantee the accuracy, timeliness or completeness of the information of this article and is not responsible for any views/opinions/comments in this article. Opinions, forecasts and estimations reflect uSmart’s assessment as of the date of this article and are subject to change. uSmart has no obligation to notify you or anyone of any such changes. You must make independent analysis and judgment on any matters involved in this article. uSmart and any directors, officers, employees or agents of uSmart will not be liable for any loss or damage suffered by any person in reliance on any representation or omission in the content of this article. The content of the article is for reference only and does not constitute any offer, solicitation, recommendation, opinion or guarantee of any securities, virtual assets, financial products or instruments. Regulatory authorities may restrict the trading of virtual asset-related ETFs to only investors who meet specified requirements. Any calculations or images in the article are for illustrative purposes only.
Investment involves risks and the value and income from securities may rise or fall. Past performance is not indicative of future performance. Please carefully consider your personal risk tolerance, and consult independent professional advice if necessary.